Table 2 Comparison of different thrombophilic parameters of the studied groups
| Variables | Control group (N = 45) | Cirrhotic patients (N = 70) | HCC patients (N = 70) | P value | Post hoc analysis |
|---|---|---|---|---|---|
| PT (s) | 12.5 ± 0.3 | 22.3 ± 5 | 20.9 ± 4.7 | 0.0000* |
P1 < 0.001 P2 < 0.001 P3 = 0.14 |
| Prothrombin conc.% | 88.7 ± 3.7 | 36.6 ± 17.6 | 39.7 ± 15 | 0.0000* |
P1 < 0.001 P2 < 0.001 P3 = 0.40 |
| TT (s) | 18.7 ± 1.41 | 19.9 ± 1.52 | 33.22 ± 13.62 | 0.0000* |
P1 = 0.73 P2 < 0.001 P3 < 0.001 |
| APTT (s) | 25.20 ± 3.2 | 27.53 ± 4.45 | 43.54 ± 18.53 | 0.0000* |
P1 = 0.55 P2 < 0.001 P3 < 0.001 |
| Fbg (g/l) | 2 (0–10) | 2.5 (0–15) | 10 (2–25) | 0.0000*** |
P1 = 0.99 P2 < 0.001 P3 < 0.001 |
| Protein C (%) | 99.8 ± 26.3 | 49.7 ± 12.5 | 54.5 ± 15.3 | 0.0000* |
P1 < 0.001 P2 < 0.001 P3 = 0.24 |
| Protein S (%) | 85.6 ± 20.4 | 61.8 ± 10.2 | 59.2 ± 18.9 | 0.0000* |
P1 < 0.001 P2 < 0.001 P3 = 0.62 |
| Antithrombin activity (%) | 88.1 ± 10.4 | 49.7 ± 11.5 | 52.5 ± 9.7 | 0.0000* |
P1 < 0.001 P2 < 0.001 P3 = 0.26 |
| Lipoprotein (a) (mg/l) | 20 (2–40) | 7 (2–14) | 11 (2–30) | 0.0000*** |
P1 < 0.001 P2 < 0.001 P3 = 0.074 |
| Homocysteine (μmol/l) | 12 (5–18) | 15 (7–29) | 26 (10–45) | 0.0000*** |
P1 = 0.13 P2 < 0.001 P3 < 0.001 |
| APCR (N (%)) | 2 (4.4%) | 6 (8.6%) | 9 (12.9%) | 0.3 | |
| FVL mutation (N (%)) | 1 (2.2%) | 2 (2.8%) | 4 (5.7%) | 0.55 |